Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Rhea-AI Summary

Vivoryon Therapeutics (Euronext: VVY) presented new analyses at the World Congress of Nephrology (March 28, 2026) reinforcing glutaminyl cyclases as targets in diabetic kidney disease (DKD). Phase 2 data from VIVIAD and VIVA-MIND showed consistent eGFR benefits, stronger effects in elderly patients with diabetes, and supportive DKD mouse-model improvements.

The company said these translational results support further development of varoglutamstat for patients with diabetes and more advanced chronic kidney disease stages.

Market Context

This announcement highlights new Phase 2 analyses of varoglutamstat, with kidney function data from ...

Analysis

This announcement highlights new Phase 2 analyses of varoglutamstat, with kidney function data from VIVIAD and VIVA-MIND and a mean baseline eGFR of 60 mL/min/1.73m2 in participants with diabetes and lower baseline kidney function. The data, complemented by DKD mouse model results, support glutaminyl cyclases as a potential target in diabetic and chronic kidney disease. Investors may watch for larger trials, progression beyond Phase 2, and additional clinical endpoints to further validate this approach.

Key Figures

Trial phase: Phase 2 Baseline eGFR: 60 mL/min/1.73m2 Conference dates: March 28-31, 2026 +3 more

6 metrics

Trial phase Phase 2 Varoglutamstat program

Baseline eGFR 60 mL/min/1.73m2 Participants with diabetes and lower baseline eGFR (mean)

Conference dates March 28-31, 2026 World Congress of Nephrology, Yokohama, Japan

Presentation date March 28, 2026 Varoglutamstat data presentation at WCN

Presentation time 5:00 pm JST / 9:00 am CET Translational validation poster (P334)

Poster number P334 Translational Validation of Glutaminyl-Cyclases in DKD

Key Terms

glutaminyl cyclases, diabetic kidney disease, DKD, glomerulosclerosis, +1 more

5 terms

glutaminyl cyclases medical

"evidence validating Glutaminyl Cyclases as Promising Targets in DKD"

Glutaminyl cyclases are enzymes that chemically modify the front end of certain proteins by converting an amino acid into a ring-shaped chemical cap, like a factory machine that snaps a protective lid onto a product. For investors, that matters because this small change can make proteins more stable or more likely to form harmful clumps, so blocking or altering the enzyme is a potential route for new drugs and can influence the value of companies developing those therapies.

diabetic kidney disease medical

"underlying molecular changes in diabetic kidney disease"

Diabetic kidney disease is a condition where high blood sugar levels caused by diabetes damage the kidneys' ability to filter waste from the blood effectively. This can lead to kidney failure over time, requiring treatments like dialysis or transplants. For investors, it highlights the importance of healthcare products and services aimed at managing diabetes and preventing its complications, which can be significant growth areas in the medical field.

DKD medical

"DKD mouse model showed significant improvements of inflammation"

Diabetic kidney disease is progressive damage to the kidneys caused by long-standing high blood sugar, where the organs gradually lose their ability to filter waste—like a coffee filter that becomes clogged over time. It matters to investors because it represents a large and growing patient population and a major area for drug development, so clinical trial results, regulatory decisions, or successful treatments can significantly affect the value of companies working on therapies or diagnostics for the condition.

glomerulosclerosis medical

"DKD mouse model showed significant improvements of inflammation, glomerulosclerosis and kidney function"

Glomerulosclerosis is permanent scarring of the tiny filters inside the kidneys that clean blood; imagine a coffee filter that becomes stiff and clogged, so it can no longer pass liquid properly. For investors, it matters because it drives demand for diagnostics, treatments and long‑term care, influences clinical trial outcomes and regulatory decisions, and can materially affect the revenues and costs of healthcare, biotech and medical-device companies.

CKD medical

"patients with diabetes and more advanced CKD stages"

Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Halle (Saale) / Munich, Germany, March 28, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that new data analyses from the Company’s varoglutamstat Phase 2 program were presented at the World Congress of Nephrology (WCN) held in Yokohama, Japan, March 28-31, 2026.

“We are very pleased with the opportunity to share our consistently compelling results with world leading experts in the kidney space at WCN, the International Society of Nephrology’s flagship event,” said Frank Weber, MD, CEO of Vivoryon. “With these new analyses we are able to deliver additional mechanistic proof points showing that inhibition of glutaminyl cyclases can effectively address the underlying molecular changes in diabetic kidney disease. The data continue to strengthen our ongoing development program dedicated to making a meaningful contribution to shaping the future of global kidney care.”

Presentation Highlights
Vivoryon has thoroughly analyzed kidney function data from the two independent Phase 2 studies VIVIAD and VIVA-MIND, with highly consistent results between the two studies, highlighting the unique potential of varoglutamstat to meaningfully improve kidney function in patients with diabetes. The new analyses presented at WCN underscore previous reports showing that the effect of varoglutamstat on eGFR observed in both studies was greater in elderly participants with diabetes compared to elderly participants without diabetes. In participants with diabetes and lower baseline eGFR (mean 60 mL/min/1.73m²), the effect size was comparable or higher than in the total population of participants with diabetes. Additionally, analysis of data from a DKD mouse model showed significant improvements of inflammation, glomerulosclerosis and kidney function. Taken together, these results add to the growing body of evidence showing that inhibition of glutaminyl cyclases is valid approach to address the underlying inflammatory and fibrotic changes in DKD and support further development of varoglutamstat in patients with diabetes and more advanced CKD stages.

Presentation Details
Presentation Date/Time: March 28, 2026, 5:00 pm JST/9:00 am CET
Poster Title: Translational Validation of Glutaminyl-Cyclases as Promising New Target for Treatment of DKD (P334)
Venue: Pacifico Yokohama, Yokohama, Japan
Presenter: Christine Wenzkowski, PhD, VP Business Development of Vivoryon

###

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com

Vivoryon Forward Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:
Investor Contact
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com

Attachment

• 2026-03-28_VVY_WCN

FAQ

What Phase 2 results did Vivoryon (VVY) present at WCN on March 28, 2026 for varoglutamstat?

The presentation highlighted consistent Phase 2 eGFR benefits across VIVIAD and VIVA-MIND studies. According to Vivoryon, analyses showed larger eGFR effects in elderly participants with diabetes and comparable or higher effects in those with lower baseline eGFR (mean 60 mL/min/1.73m2).

How did varoglutamstat perform in diabetic versus non-diabetic elderly participants in VVY's WCN data?

Varoglutamstat showed greater eGFR improvement in elderly participants with diabetes versus those without diabetes. According to Vivoryon, the effect on eGFR was consistently larger in the diabetic elderly subgroup across both Phase 2 studies.

Did Vivoryon (VVY) present preclinical DKD evidence for varoglutamstat at WCN 2026?

Yes, preclinical DKD mouse-model data showed significant improvements in inflammation, glomerulosclerosis and kidney function. According to Vivoryon, these translational results complement the clinical Phase 2 findings and support further development in DKD.

What patient population did VVY say may benefit most from varoglutamstat based on the WCN analyses?

Vivoryon emphasized potential benefit for patients with diabetes, particularly elderly patients and those with lower baseline eGFR. According to Vivoryon, effect sizes were comparable or higher in participants with mean baseline eGFR around 60 mL/min/1.73m2.

Where and when was Vivoryon's (VVY) WCN poster on glutaminyl cyclases presented?

The poster (P334) was presented March 28, 2026 at 5:00 pm JST/9:00 am CET in Pacifico Yokohama. According to Vivoryon, the presenter was Christine Wenzkowski, PhD, VP Business Development.